Novartis' Enablex For Overactive Bladder Clears FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Enablex will enter a crowded overactive bladder market in early 2005 that includes two recent entrants, Yamanouchi/GlaxoSmithKline's Vesicare and Indevus/Pliva's Sanctura. Novartis may emphasize darifenacin's "unique" action on the M3 receptor to distinguish it from competitors.
You may also be interested in...
P&G Joins Novartis’ Efforts To Market Overactive Bladder Treatment Enablex
Co-promotion agreement leaves the door open for P&G and Novartis to solicit FDA for approval of Enablex as OTC. Deal brings expanded sales force in a crowded market.
P&G Joins Novartis’ Efforts To Market Overactive Bladder Treatment Enablex
Co-promotion agreement leaves the door open for P&G and Novartis to solicit FDA for approval of Enablex as OTC. Deal brings expanded sales force in a crowded market.
Yamanouchi Will Promote Vesicare With 150 Specialty Sales Reps
FDA clears Vesicare for the treatment of overactive bladder. Yamanouchi and co-promotion partner GlaxoSmithKline will launch solifenacin in January 2005, with GSK sales reps handling primary care duties and Yamanouchi reps detailing to urologist and ob/gyns.